Literature DB >> 17360788

Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.

Shirish R Sangle, Graham R V Hughes, David P D'Cruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17360788      PMCID： PMC1856044          DOI： 10.1136/ard.2006.065623

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  What place for the new biologics in the treatment of necrotising vasculitides.

Authors:  D Jayne
Journal:  Clin Exp Rheumatol       Date:  2006 Mar-Apr       Impact factor: 4.473

2.  Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis.

Authors:  P Lamprecht; J Voswinkel; T Lilienthal; B Nolle; M Heller; W L Gross; A Gause
Journal:  Rheumatology (Oxford)       Date:  2002-11       Impact factor: 7.580

3.  Etanercept plus standard therapy for Wegener's granulomatosis.

Authors: 
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

Review 4.  Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects.

Authors:  P A Bacon
Journal:  Curr Opin Rheumatol       Date:  2005-01       Impact factor: 5.006

5.  Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

Authors:  Karina A Keogh; Steven R Ytterberg; Fernando C Fervenza; Kimberly A Carlson; Darrell R Schroeder; Ulrich Specks
Journal:  Am J Respir Crit Care Med       Date:  2005-10-13       Impact factor: 21.405

6.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

7.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.

Authors:  A D Booth; D R W Jayne; R K Kharbanda; C M McEniery; I S Mackenzie; J Brown; I B Wilkinson
Journal:  Circulation       Date:  2004-03-22       Impact factor: 29.690
  8 in total
  3 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  Novel strategy for the treatment of refractory vasculitis syndrome.

Authors:  Hidehiro Yamada
Journal:  Ann Vasc Dis       Date:  2013-02-15

Review 3.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.